Fosgonimeton Phase 1 Trials M3 Biotechnology (later Athira Pharma) completes Phase 1 safety trials of fosgonimeton, a prodrug of Dihexa
In neuronal senescence model studies, the active ingredient of the product can cross the blood-brain barrier (and act directly on neurons in vitro), increase NAD+ levels in nerve cells, protect mitochondrial function, reduce neuronal apoptosis, and promote the synthesis and release of neurotransmitters (such as dopamine and acetylcholine), thereby improving signal transduction in nerve cells
Adjacent human safety: Increlex (mecasermin) FDA label 71 pediatric patients with severe primary IGFD treated for a mean of 3.9 years
In addition to the regulation of this main transcription loop, CLOCK/BMAL1 stimulates the expression of other clock-related transcriptions, such as REV-ERB , retinoic acid-borne orphaned binders a ( ROR ), DEC1 , DEC2 , and albumin D-binding ( DBP ), which form an auxiliary loop that stabilizes the main regulatory loop (Ripperger and Schibler, 2006
67, 2005, pp